Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark

Boston Scientific, Inc. (BSX) has obtained a CE Mark for the ACURATE Prime Aortic Valve System — the newest transcatheter aortic valve replacement (TAVR) technology in its structural heart portfolio. The system builds upon the clinical performance of the ACURATE neo2 platform, featuring several enhancements, including an additional valve size, which expands the treatment range to patients with a larger anatomy.The latest development is expected to boost the company’s Interventional Cardiology Therapies, a c ...